Archive for Stock Market News

Fibrocell Science Shares Rise 60% on Acquisition News

By The Life Science Report

Source: Streetwise Reports   09/13/2019

Fibrocell Science’s shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share.

Cell and gene therapy company Fibrocell Science Inc. (FCSC:NASDAQ), which focuses on transformational autologous cell-based therapies for skin and connective tissue diseases, announced it has reached an agreement to be acquired by Castle Creek Pharmaceutical Holdings Inc., the parent company of Castle Creek Pharmaceuticals LLC.

Under the terms of the agreement, Castle Creek will acquire Fibrocell for approximately $63.3 million, including repayment of debt and other financial instruments, in cash. Fibrocell common stockholders will receive all-cash consideration of $3.00 per share. Fibrocell reports that the offer represents a 63% premium to Fibrocell’s 30-day volume weighted average price as of September 11, 2019. The transaction has already been approved by the Boards of Directors of both companies and is expected to close in Q4/19 subject to customary closing conditions, including Fibrocell shareholder approval. Upon completion of the transaction, Fibrocell will become a privately held subsidiary of Castle Creek with Fibrocell’s employees continuing as employees of the combined company.

Fibrocell’s president and CEO John Maslowski commented on the sale, “We are incredibly pleased to announce this transaction, which we believe is in the best interests of both shareholders and patients…We believe that combining with Castle Creek has a strong strategic rationale, as they have the expertise and resources necessary to continue the development of both FCX-007 and FCX-013, potentially bringing these and additional novel products to patients in need.”

Greg Wujek, CEO of Castle Creek Pharmaceuticals, stated, “Following our licensing agreement to develop and commercialize FCX-007, our experience working together on rare dermatological conditions caused us to quickly realize that Castle Creek and Fibrocell could achieve even greater synergies by combining the companies into one…With Castle Creek’s resources, Fibrocell’s gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple promising new therapies.”

Fibrocell’s portfolio includes FCX-007 and FCX-013. FCX-007 is an investigational, late-stage stage gene therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a congenital and progressive orphan skin disease caused by the deficiency of the protein COL7. A Phase 3 trial was initiated recently, and if successful, a Biologics License Application (BLA) filing is expected in 2021. The company states that FCX-007 has been granted Orphan Drug designation, Rare Pediatric Disease designation, Fast Track designation and Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. FCX-013 is described as an investigational, gene therapy candidate for the treatment of moderate to severe localized scleroderma. FCX-013 is an autologous fibroblast genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen. FCX-013 is currently enrolling for the Phase 1 portion of a Phase 1/2 clinical trial. The firm advises that the FDA has granted Orphan Drug designation, Rare Pediatric Disease designation and Fast Track designation to FCX-013.

These product candidates are expected to augment Castle Creek Pharmaceuticals’ CCP-020, an investigational, late-stage topical ointment under development for the treatment of epidermolysis bullosa simplex, further strengthening Castle Creek Pharmaceuticals as a leader in dermatology.

Castle Creek Pharmaceutical Holdings is a privately held holding company that holds and invests in companies in the orphan dermatology space. It s subsidiary Castle Creek Pharmaceuticals is a biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. The firm states that it is dedicated to developing and bringing novel therapies to those living with epidermolysis bullosa.

Fibrocell notes that it is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue by utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease.

FCSC shares opened much higher today at $2.92 (+$1.09, +59.56%) over yesterday close of $1.83. Since the open shares have traded on high volume in a very narrow trading range of $2.92–2.95/share and are currently trading at $2.92 (+$1.09 +59.56%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professional for medical advice.

( Companies Mentioned: FCSC:NASDAQ,
)

As the ECB dust settles – DAX30 CFD bulls emerge in control

By Admiral Markets

Source: Economic Events September 16, 2019 – Admiral Markets’ Forex Calendar

With the Economic calendar being quite thin as we begin the trading week, trading in the DAX30 CFD will be most likely driven by technical factors and the ECB decision’s aftermath.

Our view in general is that the ECB opened the door for further gains in the German index with the decision to cut the deposit rate to -0.5%, implementing a 2-tier system for reserve remuneration and especially re-launching QE at €20bn per month beginning November 1, and will, for as long as necessary, reinforce the accommodative impact of policy rates.

With the long sequence on H1 staying intact above 12,300 points, our target on the upside around 12,600/650 points stays active.

Only a drop below 12,300 points would darken the technical picture, switch the mode to neutral, activating the region around 12,180/200 points as a first target:

Source: Admiral Markets MT5 with MT5-SE Add-on DAX30 CFD Hourly chart (between August 26, 2019, to September 13, 2019). Accessed: September 13, 2019, at 10:00pm GMT

Source: Admiral Markets MT5 with MT5-SE Add-on DAX30 CFD Daily chart (between June 7, 2018, to September 13, 2019). Accessed: September 13, 2019, at 10:00pm GMT – Please note: Past performance is not a reliable indicator of future results, or future performance.

In 2014, the value of the DAX30 CFD increased by 2.65%, in 2015, it increased by 9.56%, in 2016, it increased by 6.87%, in 2017, it increased by 12.51%, in 2018, it fell by 18.26%, meaning that after five years, it was up by 10.5%.

Discover the world’s #1 multi-asset platform

Admiral Markets offers professional traders the ability to trade with a custom, upgraded version of MetaTrader 5, allowing you to experience trading at a significantly higher, more rewarding level. Experience benefits such as the addition of the Market Heat Map, so you can compare various currency pairs to see which ones might be lucrative investments, access real-time trading data, and so much more. Click the banner below to start your FREE download of MT5 Supreme Edition!

Download MetaTrader 5 and begin trading today!

Disclaimer: The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter “Analysis”) published on the website of Admiral Markets. Before making any investment decisions please pay close attention to the following:

  1. This is a marketing communication. The analysis is published for informative purposes only and are in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
  2. Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the Analysis.
  3. Each of the Analysis is prepared by an independent analyst (Jens Klatt, Professional Trader and Analyst, hereinafter “Author”) based on the Author’s personal estimations.
  4. To ensure that the interests of the clients would be protected and objectivity of the Analysis would not be damaged Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
  5. Whilst every reasonable effort is taken to ensure that all sources of the Analysis are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis. The presented figures refer that refer to any past performance is not a reliable indicator of future results.
  6. The contents of the Analysis should not be construed as an express or implied promise, guarantee or implication by Admiral Markets that the client shall profit from the strategies therein or that losses in connection therewith may or shall be limited.
  7. Any kind of previous or modeled performance of financial instruments indicated within the Publication should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
  8. The projections included in the Analysis may be subject to additional fees, taxes or other charges, depending on the subject of the Publication. The price list applicable to the services provided by Admiral Markets is publicly available from the website of Admiral Markets.
  9. Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, you should make sure that you understand all the risks.

By Admiral Markets

Dow notches eighth straight gain

By IFCMarkets

Dollar weakening intact despite strong retail sales report

US stocks ended marginally lower on Friday despite strong August retail sales report . The S&P 500 slipped 0.1% to 3007.39, extending gains 1% for the week. Dow Jones industrial however rose 0.2% to 27219.52. The Nasdaq slid 0.2%. The dollar weakening continued despite Commerce Department report retail sales grew above expected 4.1% on-year in August. The live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, lost 0.2% to 98.17 and is lower currently. Stock index futures point to lower openings today.

DAX leads European indexes movement

European stocks added to previous session gains on Friday buoyed by the European Central Bank rate cut and resumption of bond purchases. Both EUR/USD and GBP/USD continued climbing Friday with euro rising currently against the dollar while Pound turning lower. The Stoxx Europe 600 Index gained 0.3% led by bank and mining stocks. The DAX 30 rose 0.5% Friday to 12468.53. France’s CAC 40 advanced 0.2% and UK’s FTSE 100 added 0.3% to 7367.46.

Hang Seng leads Asian indexes losses

Asian stock indices are mostly lower today as oil prices rise. Japan’s Nikkei is closed for a holiday as yen advances against the dollar. China’s markets are lower after reports industrial output, retail sales fell short of expectations: the Shanghai Composite Index is down 0.02% and Hong Kong’s Hang Seng Index is 1.0% lower. Australia’s All Ordinaries Index ticked up 0.06% with the Australian dollar’s climb against the greenback intact.

Brent soars after drone attacks on Saudi Arabia

Brent futures prices jumped today after Sunday drone attacks on crude facilities in Saudi Arabia. Prices slipped on Friday: Brent for November settlement ended 0.3% lower at $60.22 a barrel Friday, losing 2.1% for the week.

BRENT jumps after drone attacks    09/16/2019 Market Overview IFC Markets chart

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

VIX Speculators sharply boosted their bearish bets, up for 2nd week

September 14th – By CountingPips.comReceive our weekly COT Reports by Email

VIX Non-Commercial Speculator Positions:

Large volatility speculators strongly added their bearish net positions in the VIX futures markets this week, according to the latest Commitment of Traders (COT) data released by the Commodity Futures Trading Commission (CFTC) on Friday.

The non-commercial futures contracts of VIX futures, traded by large speculators and hedge funds, totaled a net position of -93,429 contracts in the data reported through Tuesday September 10th. This was a weekly lowering of -26,787 net contracts from the previous week which had a total of -66,642 net contracts.

The week’s net position was the result of the gross bullish position (longs) falling by -16,361 contracts (to a weekly total of 96,684 contracts) while the gross bearish position (shorts) saw a gain by 10,426 contracts for the week (to a total of 190,113 contracts).

VIX speculative bearish positions pushed higher once again this week following a modest gain last week (-9,489 contracts). This week’s increase by more than -26,000 contracts is the largest one-week bearish rise in the past twenty-five weeks and puts the overall bearish level back near the -100,000 contract standing. VIX speculator bets hit a record high bearish position earlier this year in late April (-180,359 contracts) before pulling back. Bearish bets also looked to be heading that way again in late July (-144,314 contracts) before the risk-off themes of August prompted traders to sharply flee their bearish positions. The recent calming in the markets may see traders build their bearish positions back above the -100,000 contract level in coming weeks.

VIX Commercial Positions:

The commercial traders position, hedgers or traders engaged in buying and selling for business purposes, totaled a net position of 102,041 contracts on the week. This was a weekly gain of 30,167 contracts from the total net of 71,874 contracts reported the previous week.

VIX Futures:

Over the same weekly reporting time-frame, from Tuesday to Tuesday, the VIX Futures (Front Month) closed at approximately $17.67 which was a fall of $-1.85 from the previous close of $19.52, according to unofficial market data.

*COT Report: The COT data, released weekly to the public each Friday, is updated through the most recent Tuesday (data is 3 days old) and shows a quick view of how large speculators or non-commercials (for-profit traders) as well as the commercial traders (hedgers & traders for business purposes) were positioned in the futures markets.

The CFTC categorizes trader positions according to commercial hedgers (traders who use futures contracts for hedging as part of the business), non-commercials (large traders who speculate to realize trading profits) and nonreportable traders (usually small traders/speculators).

Find CFTC criteria here: (http://www.cftc.gov/MarketReports/CommitmentsofTraders/ExplanatoryNotes/index.htm).

Article By CountingPips.comReceive our weekly COT Reports by Email

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

By The Life Science Report

Source: Streetwise Reports   09/12/2019

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus.

This morning clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ), which states it is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647).

Based on these data, the firm advised that it is advancing mRNA-1647 to a dose-confirmation Phase 2 study in the near term. Preparation has also begun for a pivotal Phase 3 study designed to evaluate the efficacy of mRNA-1647 against primary CMV infection. The firm indicates that mRNA-1647 is a vaccine combining six mRNAs in a single vial, which encode for two antigens on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB).

Tal Zaks, M.D., Ph.D., chief medical officer at Moderna commented, “I am very encouraged by the ability of mRNA-1647 to induce high levels of durable immune responses that can reach or exceed the levels generated by natural CMV infection…We recognize there is an urgent need for a preventative vaccine against congenital CMV and will be advancing mRNA-1647 into a Phase 2 study in the near term to confirm the appropriate dose, while we plan for a pivotal Phase 3 study.”

Sallie Permar, M.D., Ph.D., associate dean of physician scientist development and professor of pediatrics, immunology, and molecular genetics and microbiology at Duke Medical School, added, “Cytomegalovirus is the leading infectious cause of birth defects, and there is a great need for a vaccine that blocks transmission of the virus from the mother to the fetus…These interim data are exciting because mRNA-1647 has shown the ability to induce immune responses in seronegative individuals that are greater than what is seen in those naturally infected with CMV, which is important in that natural immunity is not completely protective against congenital CMV transmission.”

The Phase 1 study, which has completed enrollment, is evaluating the safety and immunogenicity of mRNA-1647 in 169 healthy adult volunteers. The study population includes those who were naïve to CMV infection (CMV-seronegative) and those who had previously been infected by CMV (CMV-seropositive). A safety analysis indicated that the vaccine was generally well tolerated and there were no vaccine-related serious adverse events.

CMV is a common pathogen and member of the herpesvirus family. Congenital CMV infection results when infected mothers transmit the virus to their unborn child, and it is the leading infectious cause of birth defects in the U.S., with approximately 25,000 newborns in the U.S. infected every year. There is currently no approved vaccine for the prevention of CMV infection.

The company also today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against chikungunya virus.

The data from the study shows that at all three dose levels, the administration of mRNA-1944 led to detectable levels of CHKV-24 antibody in all participants, ranging from 1 µg/mL to 14 µg/mL. The firm states that these results mark the first systemic mRNA therapeutic to show production of a secreted protein in humans. mRNA-1944 is being developed with financial support from the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense. mRNA-1944 is the first development candidate from the company’s systemic therapeutics modality to start clinical testing and utilizes the same lipid nanoparticle (LNP) formulation as the company’s rare disease program for methylmalonic acidemia (mRNA-3704). A total of 22 healthy adults have been enrolled in the study to date.

Dr. Zaks advised, “These Phase 1 data represent a significant scientific breakthrough: this study shows for the first time the ability to generate therapeutic levels of a complex protein in humans through systemic administration of an mRNA, essentially instructing the body to make its own medicines.”

Moderna’s CEO Stéphane Bancel stated, “These data represent another critical milestone for the validation of Moderna’s mRNA platform in humans…This is the fifth modality for which we have shown translation from preclinical research to humans and the first demonstration of mRNA as a systemic therapeutic capable of creating high levels of protein at a well-tolerated dose. We believe these results further validate our approach, the scientific platform we have built and the potential of mRNA to become a new class of medicines. We look forward to learning from the ongoing Phase 1/2 study of mRNA-3704 for methylmalonic acidemia, the first of our rare disease programs to enter the clinic, as it utilizes the same technology demonstrated in this chikungunya study.”

Chikungunya is a mosquito-borne virus that poses a significant public health problem in tropical and subtropical regions. The disease is characterized by an acute onset of fever, rash, muscle pain and sometimes debilitating pain in multiple joints. There are no vaccines approved to prevent chikungunya infection or disease.

Moderna Inc. is a clinical stage biotechnology company headquartered in Cambridge, Mass., engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. The company has a diverse development pipeline of 22 programs with multiple clinical studies underway. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases and rare genetic diseases. The company currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc. and the Defense Advanced Research Projects Agency.

MRNA share opened today at $17.34 (+$1.42, +8.92%) over yesterday’s $15.92 closing price. The stock has traded today between $16.23 and $18.46/share and at present is trading at $16.84 (+$0.92, +5.78%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professional for medical advice.

( Companies Mentioned: MRNA:NASDAQ,
)

RoboMarkets Launches Trading Cloudflare Stocks

13 September, 2019 – Limassol, Cyprus. RoboMarkets is launching trading stocks of the American company Cloudflare Inc., which filed for an IPO and is expected to float on September 13th 2019 on the New York Stock Exchange (NYSE) with the NET ticker. From the very first trading session, RoboMarkets offers an opportunity to buy and sell both real stocks and CFDs on Cloudflare stocks in R Trader multi-asset platform.

Kiryl Kirychenka, RoboMarkets Product Manager: “Cloudflare is one of the global leaders in the SaaS segment. The company has great prospects in terms of its future growth and is of great interest from investment point of view. We are pleased to provide our clients with the opportunity to invest in Cloudflare shares from the very first day of trading”.

Cloudflare is the developer of a global cloud platform that provides companies with a set of services for protecting information and networking. At the last investment round in May 2019, Cloudflare was valued at $ 3.2 billion. The company’s revenue for the past 12 months is $ 234 million with a quarterly growth of 49% year-on-year.

About RoboMarkets

RoboMarkets is an investment company with the CySEC license No. 191/13. RoboMarkets offers brokerage services in many European countries by providing traders, who work on financial market, with access to its proprietary trading platforms. The Company’s clients have access to trading 8 types of assets and more than 11,700 trading instruments.

About R Trader

R Trader is brought to you by RoboMarkets and UMSTEL, a fintech company working on a cloud-based multi-market trading platform. R Trader enables access to over 11,000 instruments across 8 asset classes. This platform is user-friendly and guarantees maximum transaction transparency, while also being in line with the leading desktop trading terminals.

 

 

GB100 Analysis: Positive data bullish for GB100 Stock Market

By IFCMarkets

Positive data bullish for GB100

UK’s manufacturing output decline was less than expected. Will the GB100 stock index continue advancing?

UK data lately were positive on balance: contraction in manufacturing sector slowed while construction output grew in July. Manufacturing production declined 0.6% over year after 1.4% drop in June, while construction output rose 0.3% after 0.2% decline. And labor market remains strong: data indicated UK jobless rate fell back to lowest since mid-1970 – 3.8% after 3.9% in June. And British lawmakers are opposing Prime Minister Boris Johnson’s actions aimed at leading UK out of European Union without a deal in the end of October. Positive data are bullish for UK’s stock market index.

GB100 gaining above MA(200) 09/13/2019 Technical Analysis IFC Markets chart

On the daily timeframe GB100: D1 is rising after bouncing off the 200-day moving average MA(200).

  • The Donchian channel indicates uptrend: it is narrowing up.
  • The Parabolic indicator has formed a buy signal.
  • The MACD indicator is about to cross above the signal line and the gap is widening, which is a bullish signal.
  • The RSI oscillator is above 50 level but has not reached the overbought zone.

We believe the bullish momentum will continue as the price breaches above the upper boundary of Donchian channel at 7366.78. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the fractal low at 7196.94. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (7196.94) without reaching the order (7366.78), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Technical Analysis Summary

Order Buy
Buy stop Above 7366.78
Stop loss Below 7196.94

Market Analysis provided by IFCMarkets

Global equities rise as trade war concerns ease

By IFCMarkets

Dow notched seventh straight win

US stock indexes advance continued on Thursday as President Trump said he would be open to a smaller-scale, interim trade deal. The S&P 500 gained 0.3% to 3009.57. The Dow Jones industrial average added 0.2% to 27182.45. Nasdaq composite index rose 0.3% to 8194.47. The dollar weakened despite data showing core inflation rose 0.3%, above forecasts of a 0.2% gain, while the number of Americans applying for new unemployment benefits fell by 15,000 to 204,000 last week: the live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, fell 0.3% to 98.35 and is lower currently. Stock index futures point to higher openings today.

CAC 40 paces European indexes gains

European stocks extended gains on Thursday after the European Central Bank (ECB) resumed massive bond-buying. Both EUR/USD and GBP/USD resumed climbing yesterday with both pairs moving higher currently . The Stoxx Europe 600 index ended 0.2% higher as the ECB cut its deposit rate from -0.4% to -0.5%, and announced it would restart open-ended purchasing of long-term government bonds at a pace of €20 billion a month. Germany’s DAX 30 advanced 0.41% to 12410.25. France’s CAC 40 rose 0.44% while UK’s FTSE 100 added 0.1% to 7349.67 as British government published its plans for a no-deal Brexit on Wednesday night.

Nikkei leads Asian indexes gains

Asian stock indices are in green today in thin trading with markets in mainland China, Taiwan and South Korea closed for holidays. Nikkei extended gains 1.1% to 21988.29 as yen renewed its slide against the dollar. Hong Kong’s Hang Seng Index is 0.8% higher after reports China called on state firms to boost investment in crisis-hit Hong Kong. Australia’s All Ordinaries Index gained another 0.5% despite continuing Australian dollar climb against the greenback.

Nikkei rises above MA(200)    09/13/2019 Market Overview IFC Markets chart

Brent down

Brent futures prices are edging lower today. Prices advanced yesterday as OPEC and major producers reiterated their commitment to current output cuts, but didn’t announce bigger production cuts as some had expected in the wake of easing tensions between the US and Iran: November Brent crude lost 0.7% to $60.38 a barrel on Thursday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

By The Life Science Report

Source: Streetwise Reports   09/11/2019

This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million.

On Wednesday morning, T2 BioSystems Inc. (TTOO:NASDAQ) announced receipt of funding from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to advance technology for diagnosis and treatment of bloodstream infections.

The initial phase of the milestone-based contract is worth $6 million, with a potential value of up to $69 million if all contract options are exercised.

The goal of the contract is to, “enable a significant expansion of the company’s current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes,” and to “reduce the growing threat of antimicrobial resistance.”

The Massachusetts-based medical diagnostics company uses a unique T2 Magnetic Resonance detection technology to identify sepsis-causing pathogens as quickly as possible to enable faster treatment. T2 Biosystems states that its “blood tests provide actionable results in just 3-5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1-5 days or more.”

Shares reached $2.69 during Wednesday trading, up more than 88% from the prior day’s close of $1.43.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Kevin Jaillet compiled this article for Streetwise Reports LLC and is an employee of Streetwise Reports. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professional for medical advice.

( Companies Mentioned: TTOO:NASDAQ,
)

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

By The Life Science Report

Source: Streetwise Reports   09/11/2019

The company’s reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report.

In a Sept. 9 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Eidos Therapeutics Inc. (EIDX:NASDAQ) agreed to give Alexion Pharmaceuticals exclusive rights in Japan to its clinical stage therapeutic AG10 for $50 million.

AG10 is a small molecule designed to potently stabilize transthyretin (TTR), thereby halting the progression of amyloidosis and other ATTR diseases.

Rahimi discussed Eidos’ rationale behind the deal and “why it makes sense now.”

One, the transaction provides an easier way for Eidos to enter the Japanese market. By itself, Eidos would have had to conduct another pivotal study just for that.

Two, the deal is a “tack-on development that adds more to the Eidos coffers without changing existing AG10 commercial strategy,” Rahimi noted.

Three, the arrangement also serves as an initial instance of Eidos being vigorously vetted by big pharma “and emerging as an even shinier, validated diamond for others to see,” wrote Rahimi.

About the deal in general, Rahimi commented, “Taking a bird’s eye view of the ATTR-cardiomyopathy landscape, we view this as a significantly hot indicator of the number of strategics knocking on Eidos’ door for a space at the AG10 table.”

Rahimi indicated that the next two months for the San Francisco-headquartered biopharma look “rosy” with potential significant upside regardless of whether its acquisition by BridgeBio Pharma goes through. Closing would be a “significant win” for Eidos, “completing a fourfold increase in share price from about $10 lows in October 2018,” the analyst added. However, not closing would not hamper the working relationship between the two firms.

Another upcoming catalyst for Eidos is its scheduled presentation at the 2019 American Heart Association Scientific Sessions meeting in November, during which the biopharma will review the long-term safety and pharmacokinetic/pharmacodynamic results from its Phase 2 open-label extension study.

ROTH has a Buy rating and a $51 per share price target on Eidos, whose stock is currently trading at around $43.43 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Eidos Therapeutics Inc., Flash Note, September 9, 2019

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Eidos Therapeutics, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: EIDX:NASDAQ,
)